Heidi Heath
Millennium Pharmaceuticals
6 Papers
213 Citations
Heidi Heath is an academic researcher from Millennium Pharmaceuticals. The author has contributed to research in topics: Chemokine receptor & CC chemokine receptors. The author has an hindex of 4, co-authored 5 publications. Previous affiliations of Heidi Heath include Takeda Pharmaceutical Company.
Chat about Author
Papers
Chemokine receptor usage by human eosinophils. The importance of CCR3 demonstrated using an antagonistic monoclonal antibody.
Heidi Heath,Shixin Qin,Pat Rao,Lijun Wu,Greg LaRosa,Nasim Kassam,Paul D. Ponath,Charles R. Mackay +7 more
TL;DR: A mAb, 7B11, is described that is selective for CCR3 and has the properties of a true receptor antagonist and the feasibility of completely antagonizing this receptor is demonstrated.
Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding.
Lijun Wu,Greg LaRosa,Nasim Kassam,Cynthia J. Gordon,Heidi Heath,Nancy Ruffing,Howard H. Chen,Jason Humblias,Michel Samson,Marc Parmentier,John P. Moore,Charles R. Mackay +11 more
TL;DR: The second extracellular loop of CCR5 is an ideal target site for the development of inhibitors of either chemokine or HIV-1 binding to CCR4, suggesting a complicated pattern of HIV- 1 gp120 binding to different regions of C CR5, but a relatively simple pattern for chemokin binding.
424
C-C Chemokine Receptor 4 Expression Defines a Major Subset of Circulating Nonintestinal Memory T Cells of Both Th1 and Th2 Potential
David P. Andrew,Nancy Ruffing,Chang H. Kim,Wenyan Miao,Heidi Heath,You Li,Kristine E. Murphy,James Campbell,Eugene C. Butcher,Lijun Wu +9 more
TL;DR: It is shown that CCR4 is a major receptor for MDC and TARC on T lymphocytes, as anti-CCR4 mAbs significantly inhibit the migration of these cells to MDC, consistent with a role for C CR4 as a major trafficking receptor for systemic memory T cells.
218
Therapeutic antibody activation of the glucocorticoid-induced TNF receptor by a clustering mechanism
Changhao He,Rachana Maniyar,Yahel Avraham,Roberta Zappasodi,Radda Rusinova,Walter Newman,Heidi Heath,Jedd D. Wolchok,Rony Dahan,Taha Merghoub,Joel R. Meyerson +10 more
TL;DR: The divalent character of the IgG agonists confers an ability to mimic GITRL and cluster and activate GITR, and will inform the clinical development of this class of antibodies for immuno-oncology.
12